Amicus Therapeutics is a Cranberry, New Jersey based American biopharmaceutical company. The company focuses on creating treatments for rare, orphan diseases like lysosmal storage disorders. Using a Chaperone-Advanced Replacement Therapy platform, Amicus Therapeutics develops effective enzyme replacement therapies. The company is known for having the pharmaceutical industry’s broadest portfolio went it comes to small molecule pharmacological chaperones. Although Amicus has no marketed products, the pharmacological chaperone treatment migalastat, used to treat Fabry disease, is at an advanced state of development.
Amicus Therapeutics has collaborated with companies like JCR Pharmaceutical, GlaxoSmithKline and Shire to do groundbreaking research and development on effective medical treatments. The company has been trading on NASDAQ under the symbol FOLD since 2007. Prior to that it received funding from New Enterprise Associates, Radius Ventures, Canaan Partners as well as other venture capital firms. Amicus Therapeutics expanded into a second research site in San Diego in 2008. The company doesn’t have its own manufacturing capability. Instead, it relies on contract manufacturing.
The Michael J. Fox Foundation gave Amicus Therapeutics a $500,000 grant in 2010 to help support the company’s collaborative studies with UCLA’s David Geffen School of Medicine. The Alzheimer’s Drug Discovery Foundation gave Amicus Therapeutics a $210,300 grant that same year in support of the pre-clinical work the company was doing at the Alzheimer’s Disease Research Center as part of a collaboration at Mount Sinai with the Icahn School of Medicine.
Amicus Therapeutics acquired Callidus Biopharma, one of it’s competitors in 2013. This gave Amicus the intellectual property and proprietary materials necessary for the creation of the enzyme replacement therapy treatment used for Pompe disease. The company continued to grow in 2015 when it paid cash and stock of $947 million to acquire Scioderm (Google Finance).
One key member of the company’s corporate governance team is John F. Crowley. He has been CEO since 2005 and became chairman of the board in 2010. The COO is Bradley L Campbell and William D. Baird III is CFO. Former board chairman Donald Hayden, Jr. is now the company’s Lead Independent Director. The Chief Scientific Officer of Amicus Therapeutics is David Lockhart.
Looking to work for Amicus Therapeutics? Indeed
The motives of a number of political donors in the U.S. can often be difficult to define, but the well-known liberal and donor to a number of Democrat’s George Soros seemed to show in 2015 and 2016 that he was dedicated to fighting on behalf of Democrat Hillary Clinton, but also a dedicated anti Donald Trump campaigner. For George Soros any free and open election should be fought over more than simply the personality of those on the ballot, but should also see every voter looking to explore the values and policies of the individuals and parties they are running on behalf of; after being let down by the lack of liberal causes pushed forward by President barrack Obama, Soros has made it his personal crusade to make sure the liberal causes the Hungarian born financial expert has held dear throughout his life. Read more at The New York Times about George.
Politico reports George Soros made his initial decision to back the campaign of former Secretary of State Clinton for the 2016 Presidential election campaign was based on his own sense of having made a mistake in backing President Barrack Obama in 2008 over Clinton. Clinton and Soros are reported to have built a strong political relationship over the course of three decades that returned to full levels of cooperation when Clinton was preparing for her run at The White House in the buildup to the 2016 election cycle; aides for Clinton have reported former refugee George Soros was given an open line to the former First Lady in a bid to make sure her own vision for the future of the U.S. reflected the policies George Soros hoped to see put into place. Although he is now a U.S. citizen the Hungarian born George Soros has always been willing to fight for the rights of those within the U.S. and those affected by U.S. policies across the planet.
Learn more: http://bigthink.com/paul-ratner/why-does-the-right-hate-george-soros
Although it is easy to express the support George Soros has shown for Hillary Clinton across the 2016 election cycle, the antipathy he feels for now President Donald Trump is also easy to see as Soros has been a fierce critic of the newly elected President. One of the major ways Soros looked to fight the rise of Trump has been through the mobilization of wealthy Democrat donors from across the U.S. Despite the victory of President Trump in 2016 the work to fight his right wing agenda looks set to continue for George Soros and his fellow members of the Democracy Alliance group of Democrat supporters who met soon after the election was completed in a bid to formulate plans for returning Democrat’s to power in Washington and fighting the right wing plans of Trump. Read this story about George at Politico.com.
Bruce Levenson’s name became better known to the public thanks to his time as Governor of the Atlanta Hawks, but now he’s hoping to increase his profile by aligning himself more closely with his philanthropic efforts. Partnering up with his wife Karen, Levenson started the Do Good Institute at the University of Maryland, helping undergrad students explore the many ways their entrepreneurial pursuits can actually do a little good in the world.
According to PR Newswire, Levenson’s Do Good Institute focuses on undergrad students that want to combine their philanthropic efforts with their professional careers. Levenson hopes that by combining the two in young people, worthwhile causes will receive the organizational structure of a sound business and be able to be more effective in meeting their goals of affecting positive change.
The Do Good Institute is by no means Bruce Levenson’s first foray into the world of philanthropy, and the understanding of that world lead to the acquisition of nearly $100 million in seed funding. This made it possible for students like Ben Simon to set up organizations that tackled issues that mattered to them most. Simon has been at the founding of Food Recovery Network, which tackled waste issues on campus, and Imperfect Produce, which help the poor access fruits and vegetables at reduced cost.
Simon is just one example of the kind of leadership Levenson hopes to foster through the Do Good Initiative. And he believes that it will be an organization that will spread to other campuses, bypassing the fear of obsolescence many traditional education programs feel in the digital age. Levenson hopes to see the Do Good Initiative attract forward thinking young people ready to engage the real world with causes that will make it more sustainable for all by applying a smart business approach.
About Bruce Levenson
Since 1977, Bruce Levenson and business partner Ed Peskowitz have run the United Communications Group. Theirs is one of the largest business information companies in the world, and in their 40 years they’ve been able to service more than two million clients in disparate industries.
Levenson has a long history championing charitable causes, most notably from his position as President of the I Have a Dream Foundation. Along with his wife Karen, Levenson founded the Center for Philanthropy and Nonprofit Leadership which is headquartered at the University of Maryland.
Read More: http://www.espn.com/nba/story/_/id/11493472/jason-whitlock-bruce-levenson-atlanta-hawks